Beyond The Numbers: 7 Analysts Discuss Lexicon Pharmaceuticals Stock
Portfolio Pulse from Benzinga Insights
Lexicon Pharmaceuticals (NASDAQ:LXRX) has received 7 analyst ratings in the past three months, all of which are bullish. The average 12-month price target is $10.00, with no changes in recent months. The company has shown significant revenue growth but faces challenges with negative net margins, ROE, and ROA, and a high debt-to-equity ratio.
September 27, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lexicon Pharmaceuticals has received 7 bullish analyst ratings with a consistent price target of $10.00. The company shows strong revenue growth but struggles with negative net margins, ROE, and ROA, and a high debt-to-equity ratio.
The unanimous bullish ratings from analysts suggest positive sentiment towards Lexicon Pharmaceuticals, likely supporting short-term stock price appreciation. However, financial challenges such as negative net margins and high debt may temper long-term optimism.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100